Browsing Tag
Neuro-Oncology
6 posts
What REYOBIQ’s Phase 1 data means for the future of CNS-directed radiopharmaceutical platforms
What does REYOBIQ’s Phase 1 data reveal about the future of CNS-targeted radiopharmaceuticals? Explore the broader neuro-oncology implications.
Could Pixclara become the missing imaging tool in U.S. glioma care after FDA NDA acceptance?
Could Pixclara transform U.S. glioma imaging after FDA NDA acceptance? Explore what Telix Pharmaceuticals Limited’s September catalyst could change next.
Why pediatric ependymoma inclusion may be the bigger strategic signal for Plus Therapeutics
Why pediatric ependymoma may be the bigger strategic signal for Plus Therapeutics and what it means for REYOBIQ’s 2026 growth roadmap. Read more.
Radiopharm Theranostics RAD 101 hits primary endpoint in 90% of brain metastasis patients at second Phase 2b interim analysis
Radiopharm Theranostics RAD 101 achieves 90% PET-MRI concordance in brain metastases Phase 2b trial. Full data due June 2026. Read more.
From lab validation to clinical execution: Adaptin Bio advances a novel glioblastoma therapy toward trials
Find out how Adaptin Bio is moving a novel glioblastoma therapy from lab validation into early clinical execution and what this step means for brain cancer research.
Telix Pharmaceuticals submits NDA for Pixclara to advance brain cancer imaging
Telix Pharmaceuticals Limited (ASX: TLX) has taken a significant step in the realm of neuro-oncology by submitting a…